ABSTRACT
Individualized medicine based on accurate assessment of prognosis and prediction of response to specific therapy has been the Holy Grail of modern oncology. Obviously, we have not achieved that goal with morphology alone and, even with the advances in molecular pathology, efforts to achieve such a goal have often been frustrating for two main reasons:
• the paucity of candidate markers to examine
• the difficulty of getting access to banked tissues from large randomized clinical trials with proper sample size.
